| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
| Ausblick | ||||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 86.33 |
| Novartis AG | 7.57 |
| Sandoz Family Foundation | 3.91 |
| UBS Asset Management Switzerland AG | 2.45 |
| Government Pension Fund - Global (The) | 2.38 |
| Credit Suisse Asset Management (Schweiz) AG | 2.20 |
| Novartis Foundation For Employee Participation | 2.10 |
| Vanguard Total International Stock Index Fund | 1.19 |
| Vanguard Health Care Fund | 0.99 |
| Vanguard Developed Markets Index Fund | 0.71 |
| Dodge & Cox International Stock Fund | 0.65 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 125'161 | 103'914 | 105'794 | 104'323 | 101'703 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.41 | 0.45 | 0.43 | 0.45 | 0.47 |
Bilanz (in Mio. EUR) - Aktiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 35'058 | 28'570 | 26'229 | 41'656 | 34'149 |
| Summe Anlagevermögen | 109'132 | 81'944 | 83'492 | 89'912 | 80'725 |
| Summe Aktiva | 143'578 | 114'665 | 116'848 | 123'811 | 112'657 |
Bilanz (in Mio. EUR) - Passiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 31'634 | 28'225 | 33'462 | 28'268 | 25'821 |
| Summe Fremdkapital | 66'003 | 60'872 | 66'759 | 62'015 | 57'679 |
| Summe Eigenkapital | 77'575 | 53'793 | 50'090 | 61'796 | 54'978 |
| Summe Passiva | 143'578 | 114'665 | 116'848 | 123'811 | 112'657 |
Adresse
| Lichtstrasse 35, 4056 Basel | |
| Telefon | +41 (61) 324-11-11 |
| Fax | +41 (61) 324-80-01 |
| URL | http://www.novartis.com |
Management
|
Ana de Pro Gonzalo
Non-Executive Director |
|
Andreas von Planta
Independent Non-Executive Director |
|
Bridgette P. Heller
Director |
|
Charles L. Sawyers
Independent Non-Executive Director |
|
Charlotte Pamer-Wieser
Secretary |
|
Daniel Hochstrasser
Director |
|
Frans van Houten
Independent Non-Executive Director |
|
Hans Jörg Reinhardt
Non-Executive Chairman |
|
Harry Werner Kirsch
Chief Financial Officer |
|
Jeremy Sohn
Vice President, Head of Business Development |
|
John D. Young
Director |
|
Karen L. Hale
Chief Legal Officer |
|
Kees Roks
Chief Audit Officer |
|
Klaus Moosmayer
Chief Ethics, Risk & Compliance Officer |
|
Linda Kanitra
Associate Director-Drug Development |
|
Marco Gadola
Senior Auditor |
|
Mary Elizabeth Doherty
Independent Non-Executive Director |
|
Nancy C. Andrews
Independent Non-Executive Director |
|
Patrice Bula
Lead Independent Director |
|
Robert Kowalski
Chief People & Organization Officer |
|
Ronny Gal
Chief Strategy & Growth Officer |
|
Samir Shah
Head-Investor Relations |
|
Shreeram Aradhye
Chief Medical Officer |
|
Simon Brown
Chief Learning Officer |
|
Simon E. Moroney
Vice Chairman |
|
Steffen Lang
President-Operations |
|
Ton Büchner
Independent Non-Executive Director |
|
Vasant Narasimhan
Chief Executive Officer |
|
William Thomas Winters
Independent Non-Executive Director |